Takeda Canada Inc. ("Takeda") is pleased to announce that Ontario Drug Benefit (ODB) include FruzaqlaTM (fruquintinib capsules) in the list of drugs eligible for funding through the Exceptional Access Program (EAP) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for available standard therapies. This treatment is eligible for reimbursement if specific clinical criteria are met.

mCRC refers to cancer of the colon that has spread to other parts of the body (called distant metastasis), such as to the liver or lungs.2 Colorectal cancer is the third most diagnosed cancer in Ontario with an estimated Approximately 70percent of patients with CRC will experience metastatic disease, whether at diagnosis or after treatment with metastases being the main cause of CRC-related death.3,4

Ontario is the latest province to reimburse FRUZAQLA following Quebec, British Columbia, New Brunswick, Nova Scotia and Saskatchewan. FRUZAQLA received market authorization by Health Canada in September 2024 and has received a positive reimbursement recommendation by Canada's Drug Agency (CDA-AMC) and Institut national d'excellence en santé et services sociaux (INESSS).